author-photo

Paul Newbold

University of Nottingham
University of Illinois at Urbana–Champaign

180

Papers

16661

Citations

Citation Trend

Filter By

Papers (180) Sort By

Journal Conference Others

The Effect of Benralizumab On Allergen-Induced Responses In Subjects With Mild Allergic Asthma

2021 The Journal of Allergy and Clinical Immunology
Show All
- Source
- Cite
- Save
Citations (0)
BLOOD EOSINOPHIL COUNT AND FRACTIONAL EXHALED NITRIC OXIDE AS A COMBINED PREDICTOR OF TREATMENT RESPONSE TO BENRALIZUMAB FOR PATIENTS WITH SEVERE, EOSINOPHILIC ASTHMA

2020 Chest
Show All
- Source
- Cite
- Save
Citations (0)
Influence of Key Clinical Baseline Characteristics on Benralizumab Response for Patients with Severe, Uncontrolled Asthma and Moderate Blood Eosinophilia

2020 The Journal of Allergy and Clinical Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Statistics for Business and Economics, ebook, Global Edition

2019
Show All
- Source
- Cite
- Save
Citations (0)
Benralizumab treatment and SARP cluster analysis

2019 European Respiratory Journal
Show All
- Source
- Cite
- Save
Citations (1)
P221 BENRALIZUMAB TREATMENT IS NOT ASSOCIATED WITH ORAL CORTICOSTEROID–LIKE INCREASES IN WEIGHT AND BLOOD PRESSURE

2019 Annals of Allergy Asthma & Immunology
Show All
- Source
- Cite
- Save
Citations (1)
The anti-IL-13 biologic tralokinumab did not alter expression of T2 and T17 transcription factors GATA3 and RORyT in bronchial biopsies

2019 European Respiratory Journal
Show All
- Source
- Cite
- Save
Citations (0)
Benralizumab for the Prevention of COPD Exacerbations.

2019 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (85)
Baseline predictors of being exacerbation-free during 2 years of benralizumab treatment

2019 European Respiratory Journal
Show All
- Source
- Cite
- Save
Citations (1)
P104 TOTAL NASAL SYMPTOM SCORE IMPROVEMENT WITH BENRALIZUMAB FOR PATIENTS WITH SEVERE, EOSINOPHILIC ASTHMA

2019 Annals of Allergy Asthma & Immunology
Show All
- Source
- Cite
- Save
Citations (0)